Inhibrx Biosciences, Inc. (INBX) Revenue History
Annual and quarterly revenue from 2016 to 2024
Compound Annual Growth Rate (CAGR)
Loading revenue history...
Revenue Growth Metrics
Revenue Breakdown (FY 2024)
INBX's revenue distribution by segment and geography for fiscal year 2024
By Product/Segment
INBX Revenue Analysis (2016–2024)
As of March 1, 2026, Inhibrx Biosciences, Inc. (INBX) generated trailing twelve-month (TTM) revenue of $1.4 million. The most recent quarter (Q3 2025) recorded $0 in revenue, down 100.0% sequentially.
Looking at the longer-term picture, INBX's 5-year compound annual growth rate (CAGR) stands at -53.4%, indicating revenue contraction over this period. The company achieved its highest annual revenue of $12.8 million in 2020.
Revenue diversification analysis shows INBX's business is primarily driven by License, Non-Affiliate (100%). With over half of revenue concentrated in License, Non-Affiliate, the company maintains significant focus in this area while developing other growth vectors.
When compared to Healthcare sector peers including INCY (+21.2% YoY), GMAB (+21.0% YoY), and EXEL (+9.9% YoY). Compare INBX vs INCY →
Peer Comparison
Compare INBX's revenue metrics with industry peers
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| INBXCurrent | $1M | - | -53.4% | -165724.0% | |
| INCY | $5.1B | +21.2% | +14.0% | 26.1% | |
| GMAB | $21.5B | +21.0% | +32.0% | 31.1% | |
| EXEL | $2.3B | +9.9% | +18.6% | 37.6% | |
| IBRX | $15M | +1026.0% | +221.4% | -2334.2% | |
| MRUS | $35M | +55.9% | +4.7% | -753.0% |
Historical Revenue Data
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2024 | $200K | -88.9% | $-2,085,000 | -1042.5% | $-331,448,000 | -165724.0% |
| 2023 | $1.8M | -17.9% | $609K | 33.8% | $-219,221,000 | -12178.9% |
| 2022 | $2.2M | -69.2% | $-107,994,000 | -4926.7% | $-129,117,000 | -5890.4% |
| 2021 | $7.1M | -44.4% | $4.4M | 62.3% | $-76,564,000 | -1074.6% |
| 2020 | $12.8M | +40.9% | $-60,687,000 | -473.8% | $-67,443,000 | -526.6% |
| 2019 | $9.1M | +21.2% | $-38,814,000 | -426.9% | $-43,714,000 | -480.7% |
| 2018 | $7.5M | -5.7% | $-25,954,000 | -346.1% | $-29,513,000 | -393.5% |
| 2017 | $8.0M | +19.2% | $-17,560,000 | -220.9% | $-19,728,000 | -248.2% |
| 2016 | $6.7M | - | $-10,325,000 | -154.9% | $-12,146,000 | -182.2% |
See INBX's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs INBX Undervalued?
See our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare INBX vs AGIO
See how INBX stacks up against sector leader Agios Pharmaceuticals, Inc..
Start ComparisonFrequently Asked Questions
Is INBX's revenue growth accelerating or slowing?
INBX TTM revenue: $1M. YoY growth: N/A. 5-year CAGR: -53.4%.
What is INBX's long-term revenue growth rate?
Inhibrx Biosciences, Inc.'s 5-year revenue CAGR of -53.4% reflects the variable expansion pattern. Current YoY growth of N/A is near this long-term average.
How is INBX's revenue distributed by segment?
INBX reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2016-2024 are available for download. Segment mix reveals concentration and diversification trends.